Literature DB >> 1466470

Metabolism of ketamine stereoisomers by human liver microsomes.

E D Kharasch1, R Labroo.   

Abstract

Ketamine is used clinically as a racemic mixture of optical isomers that differ in their analgesic properties and psychomimetic effects. Administered individually, or together as the racemate, ketamine enantiomers differ in their hepatic clearance and duration of anesthetic effect. S(+) ketamine exhibits a greater clearance and faster anesthetic recovery compared to the racemate and a greater clearance compared to R(-) ketamine. Ketamine undergoes extensive hepatic metabolism, primarily via N-demethylation to norketamine, yet little is known about the human metabolism of ketamine enantiomers. The purpose of this investigation therefore was to characterize ketamine racemate and enantiomer metabolism by human liver and to test the hypothesis that differences in hepatic ketamine enantiomer metabolism can account for observed differences in ketamine enantiomer pharmacokinetics. Ketamine N-demethylation by microsomes from three human livers was measured by gas chromatography-mass spectrometry. At ketamine concentrations typically achieved during anesthesia (5 microM), the rate of S(+) ketamine demethylation was 20% greater than that of R(-) ketamine and 10% greater than that of the racemate (P < .05). At all ketamine concentrations, the rate of racemate demethylation was less than the sum of the rates for the individual enantiomers, reflecting a metabolic enantiomeric interactin whereby one ketamine enantiomer inhibits the metabolism of the other enantiomer. N-demethylation of racemic ketamine and each enantiomer was catalyzed by two apparent enzymes, a high affinity-low capacity enzyme (Km1 30-50 microM, Vmax1 2-6 nmoles.min-1 x nmole-1) and a low affinity-high capacity enzyme (Km2 600-800 microM, Vmax2 9-15 nmoles.min-1 x nmole-1).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1466470     DOI: 10.1097/00000542-199212000-00022

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  24 in total

1.  Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing.

Authors:  Samuel Fanta; Mari Kinnunen; Janne T Backman; Eija Kalso
Journal:  Eur J Clin Pharmacol       Date:  2015-03-01       Impact factor: 2.953

2.  Antinociceptive effects, metabolism and disposition of ketamine in ponies under target-controlled drug infusion.

Authors:  M Knobloch; C J Portier; O L Levionnois; R Theurillat; W Thormann; C Spadavecchia; M Mevissen
Journal:  Toxicol Appl Pharmacol       Date:  2006-07-03       Impact factor: 4.219

Review 3.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 4.  Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications.

Authors:  Jaclyn N Highland; Panos Zanos; Lace M Riggs; Polymnia Georgiou; Sarah M Clark; Patrick J Morris; Ruin Moaddel; Craig J Thomas; Carlos A Zarate; Edna F R Pereira; Todd D Gould
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

5.  Enantioselective inhibition of d-serine transport by (S)-ketamine.

Authors:  Nagendra S Singh; Michel Bernier; Simonetta Camandola; Mohammed A Khadeer; Ruin Moaddel; Mark P Mattson; Irving W Wainer
Journal:  Br J Pharmacol       Date:  2015-07-31       Impact factor: 8.739

6.  Stereoselective and regiospecific hydroxylation of ketamine and norketamine.

Authors:  Zeruesenay Desta; Ruin Moaddel; Evan T Ogburn; Cong Xu; Anuradha Ramamoorthy; Swarajya Lakshmi Vattem Venkata; Mitesh Sanghvi; Michael E Goldberg; Marc C Torjman; Irving W Wainer
Journal:  Xenobiotica       Date:  2012-05-21       Impact factor: 1.908

Review 7.  Advances in translational neuropathic research: example of enantioselective pharmacokinetic-pharmacodynamic modeling of ketamine-induced pain relief in complex regional pain syndrome.

Authors:  Michael Sabia; Robert A Hirsh; Marc C Torjman; Irving W Wainer; Niti Cooper; Richard Domsky; Michael E Goldberg
Journal:  Curr Pain Headache Rep       Date:  2011-06

8.  Antitumor activity of DMAKO-05, a novel shikonin derivative, and its metabolism in rat liver microsome.

Authors:  Xu Zhang; Ru-Bing Wang; Wen Zhou; Sui Xiao; Qing-Qing Meng; Shao-Shun Li
Journal:  AAPS PharmSciTech       Date:  2014-10-02       Impact factor: 3.246

9.  Acute ketamine administration alters the brain responses to executive demands in a verbal working memory task: an FMRI study.

Authors:  R A E Honey; G D Honey; C O'Loughlin; S R Sharar; D Kumaran; E T Bullmore; D K Menon; T Donovan; V C Lupson; R Bisbrown-Chippendale; P C Fletcher
Journal:  Neuropsychopharmacology       Date:  2004-06       Impact factor: 7.853

10.  Subdissociative dose ketamine produces a deficit in manipulation but not maintenance of the contents of working memory.

Authors:  Rebekah A E Honey; Danielle C Turner; Garry D Honey; Sam R Sharar; D Kumaran; E Pomarol-Clotet; P McKenna; B J Sahakian; T W Robbins; P C Fletcher
Journal:  Neuropsychopharmacology       Date:  2003-11       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.